Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssen’s Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC)

Архивировано 05.10.2021: jnj.com-2019-10-31-ebola-500000-drc.pdf

Источник: Ernie Knewitz. Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssen’s Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC). Johnson & Johnson, 2019-10-31

The government of the Democratic Republic of the Congo (DRC) has decided to use the investigational Ebola vaccine regimen currently being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson as part of an expanded public health initiative to help contain the country’s Ebola outbreak. More than 3,000 cases, including more than 2,000 deaths, have been reported in the DRC outbreak to date, making it second only to the 2014-2016 West Africa epidemic. To help protect people at risk of Ebola, Janssen has committed to donate up to 500,000 vaccine regimens in support of a new clinical study in the DRC. The first batches of vaccine have been shipped to the country.